Hand-foot syndrome with scleroderma-like change induced by the oral capecitabine: A case report

Korean Journal of Internal Medicine

Volumn 22, Issue 2, 2007, Pages 109-112

  Lee, Sehe Dong ^a   Kim, Hye Jeong ^a   Hwang, Seung Jae ^a   Kim, Yoon Jung ^a   Nam, Seung Hyun ^a   Kim, Bong Seog ^a  

^a Seoul Veterans Hospital   (South Korea)

Author keywords

Capecitabine; Hand foot syndrome; Scleroderma

Indexed keywords

CAPECITABINE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL;

AGED; ARTICLE; CASE REPORT; DESQUAMATION; DISEASE COURSE; FOOT SOLE; HAND FOOT SYNDROME; HAND PALM; HUMAN; HYPERPIGMENTATION; KERATODERMA; MALE; MULTIPLE CYCLE TREATMENT; RECOMMENDED DRUG DOSE; SCLERODERMA; SKIN ULCER; CHEMICALLY INDUCED DISORDER; HAND DISEASE; LOCALIZED SCLERODERMA; ORAL DRUG ADMINISTRATION; RISK FACTOR; SKIN DISEASE;

ADMINISTRATION, ORAL; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; FLUOROURACIL; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; MALE; RISK FACTORS; SCLERODERMA, LOCALIZED;

EID: 34748824202     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2007.22.2.109     Document Type: Article

References (14)

1. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274-1281, 1998
2. Budman DR, Meropol NJ, Reigner B, Creaven PJ, Lichtman SM, Berghorn E, Behr J, Gordon RJ, Osterwalder B, Griffin T. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol 16:1795-1802, 1998
3. SchullerJ, CassidyJ, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45:291-297, 2000
4. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19:2282-2292, 2001
5. van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19:4097-4106, 2001
6. Cassidy J, Twelves C, van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendric J, Maroun J, Marshall J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schilsky RL. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13:566-575, 2002
7. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485-493, 1999
8. Abushullaih S, Saad ED, Munsell M, Hoff PM. Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. Cancer Invest 20:3-10, 2002
9. Lokich JJ, Moore C. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 101:798-799, 1984
10. Meta-Analysis Group in Cancer. Toxicity of Fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 16:3537-3541, 1998
11. Capecitabine (Xeloda). In: Physicians' desk reference. 55th ed. p. 2606-2809, Montvale, Medical Economics, 2001
12. Narasimhan P, Narasimhan S, Hitti IF, Rachita M. Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature. Cutis 73:101-106, 2004
13. Baack BR, Burgdorf WH. Chemotherapy-induced acral erythema. J Am Acad Dermatol 24:457-461, 1991
14. Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, VonRoenn J. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 75:2169-2173, 1995